Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

TLDR

• Novo Nordisk’s oral Wegovy pill achieved 3,071 retail prescriptions within four days of its January 5, 2026 launch
• Novo’s shares rose 6.5% to their highest level since September 2025 following the prescription data release
• Eli Lilly’s Zepbound injection currently dominates weight loss market sales with FDA decision on Lilly’s oral pill expected by April 2026
• Analysts project Novo’s oral Wegovy could generate $1 billion in 2026 sales if the company maintains first-mover advantage
• Both companies are pursuing cash-paying customers through retail pharmacies and telehealth platforms

Novo Nordisk’s oral Wegovy weight loss pill recorded 3,071 retail prescriptions during its first four days of availability. The medication launched January 5, 2026, becoming the first pill-based weight loss treatment on the market.

Novo Nordisk A/S, NVO

IQVIA data tracked the prescription numbers across retail pharmacies. The figures exclude online pharmacy sales, including prescriptions filled through Novo’s NovoCare Pharmacy platform.

Novo Nordisk’s stock price increased 6.5% after the company released the early sales data. The shares reached their highest trading level since September 2025. The Danish pharmaceutical company had experienced stock declines in 2025 following profit warnings and reduced growth forecasts.

Novo Nordisk Distribution Strategy

The company is selling oral Wegovy through CVS and Costco retail pharmacy locations. Novo also formed partnerships with telehealth companies Ro, LifeMD, WeightWatchers, and GoodRx for direct consumer access.

Ro CEO Zach Reitano reported positive early feedback on the oral Wegovy pill. The medication is attracting new patients alongside existing users of other GLP-1 weight loss treatments.

Novo is concentrating on the U.S. market before international expansion. The company aims to avoid the supply shortages that occurred during the 2021 launch of injectable Wegovy.

Berenberg analysts forecast the oral Wegovy pill could produce $1 billion in revenue throughout 2026. This estimate depends on Novo maintaining market leadership before competing products launch.

Eli Lilly Market Position

Eli Lilly controls the weight loss injection market with its Zepbound medication. Zepbound received FDA approval in late 2023 and now generates higher quarterly sales than Wegovy injections.

Head-to-head clinical trials demonstrated Zepbound produced superior weight loss results compared to Wegovy. Eli Lilly’s market capitalization stands at $982 billion versus Novo Nordisk’s $210 billion valuation.

The FDA will issue a decision on Eli Lilly’s oral weight loss pill by April 2026. Approval would introduce direct competition to Novo’s oral Wegovy in the pill-based weight loss market.

UBS analysts indicated that reaching 400,000 first-quarter prescriptions would match Eli Lilly’s Zepbound launch performance. That level would surpass the original injectable Wegovy launch results from 2021.

Barclays analysts noted potential challenges for Novo’s oral Wegovy sales. Price competition and changes to state insurance coverage policies could reduce revenue growth.

Weight Loss Drug Pipeline Development

Eli Lilly is advancing orforglipron, its experimental oral weight loss medication. The company is also testing retatrutide, which achieved 28.7% mean weight loss in 68-week clinical trials.

Lilly operates a diverse pharmaceutical portfolio beyond weight loss drugs. Cancer treatment Verzenio and psoriasis medication Taltz each generate over $1 billion in annual revenue.

Novo Nordisk submitted an FDA application for CagriSema, another weight loss therapy under development. The company continues investing in its weight loss treatment pipeline while competing against Lilly.

Both pharmaceutical companies are targeting consumers who pay out-of-pocket rather than through insurance coverage. This business model shift represents a departure from traditional insurance-based pharmaceutical pricing.

Industry analysts plan to review prescription trends over multiple weeks. First-quarter sales data will provide clearer indicators of Novo’s competitive position before Eli Lilly’s oral medication potentially enters the market in spring 2026.